Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ESRRA | P11474 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 2/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1941122 | 0.87 | THRA (0.45) | CYP1A2CYP2C9ALDH1A1KDM4ETHRA | |
| SCHEMBL25935035 | 0.83 | THRA (0.54) | CYP1A2CYP2C9ESRRACFTRALOX5AP | |
| SCHEMBL16726459 | 0.83 | THRA (0.60) | ALDH1A1ESRRACFTRKDM4ETHRA | |
| SCHEMBL1941888 | 0.83 | CFTR (0.43) | CYP1A2CYP2C9ALDH1A1ESRRACFTR | |
| SCHEMBL25317633 | 0.82 | THRA (0.47) | CYP1A2CYP2C9ALDH1A1ESRRACFTR | |
| SCHEMBL4841210 | 0.82 | THRA (0.47) | CYP1A2CYP2C9ESRRACFTRALOX5AP | |
| SCHEMBL27647625 | 0.82 | THRA (0.50) | CYP1A2CYP2C9ESRRACFTRALOX5AP | |
| SCHEMBL22979384 | 0.82 | KDM4E (0.51) | CYP1A2CYP2C9ALDH1A1ESRRACFTR | |
| SCHEMBL1941489 | 0.81 | XDH (0.43) | CYP1A2CYP2C9ALDH1A1ESRRACFTR | |
| SCHEMBL1941633 | 0.81 | CFTR (0.42) | CYP1A2CYP2C9ALDH1A1ESRRACFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1619185-B1 | 4,4-DIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2011-06-15 | — | — | EP | disclosed |
| US-7807664-B2 | 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or salt thereof | ASTELLA PHARMA INC. (JP) | 2010-10-05 | — | — | US | disclosed |
| CN-101279971-A | 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzoazepine derivative or salt of the same | ASTELLAS PHARMA INC (JP) | 2008-10-08 | — | — | CN | disclosed |
| CN-100404511-C | 4, 4-difluoro-1, 2,3, 4-tetrahydro-5H-1-benzazepine * derivatives or salts thereof | ASTELLAS PHARMA INC (JP) | 2008-07-23 | — | — | CN | disclosed |
| US-20070167429-A1 | 4,4-Difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or salt thereof | ASTELLAS PHARMA INC. | 2007-07-19 | — | — | US | disclosed |
| US-7183271-B2 | 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20060122170-A1 | 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof | ASTELLA PHARMA INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| CN-1780819-A | 4, 4-difluoro-1, 2,3, 4-tetrahydro-5H-1-benzazepine * derivatives or salts thereof | ASTELLAS PHARMA INC (JP) | 2006-05-31 | — | — | CN | disclosed |
| EP-1619185-A1 | 4,4-DIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2006-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167429-A1 | 4,4-Difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or salt thereof | SLC5A1, SLC5A2, DPP4 | CYP1A2 3430/4885CYP2C9 2018/4885ALDH1A1 414/4885 |
| US-20060122170-A1 | 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof | SLC5A1, SLC5A2, DPP4 | CYP1A2 3430/4885CYP2C9 2018/4885ALDH1A1 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.